Pfizer (NYSE:PFE) Stock Price Down 1.3% – Should You Sell?

Pfizer Inc. (NYSE:PFE) was down 1.3% during mid-day trading on Monday . The stock traded as low as $27.17 and last traded at $27.2790. Approximately 40,251,273 shares traded hands during mid-day trading, a decline of 16% from the average daily volume of 48,190,391 shares. The stock had previously closed at $27.65.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 readout for PADCEV combination in muscle‑invasive bladder cancer could be a meaningful oncology commercial and label opportunity for Pfizer. Pfizer and Astellas PADCEV Phase 3 Results
• Positive Sentiment: Argus upgraded Pfizer from Hold to Buy and set a $35 price target, signaling bullish analyst support that can underpin demand. Argus upgrade coverage
• Positive Sentiment: Technical and institutional signs — social chatter about a technical recovery, Norges Bank stake and notable options/yield interest — are drawing investor attention and supporting upside momentum. QuiverQuant summary
• Neutral Sentiment: Market commentary and stock‑grade pieces debate whether to buy/hold after an ~11% YTD rally — these narratives (for example Yahoo/Zacks pieces) keep volume and volatility elevated but don’t add a single catalytic driver. Yahoo: Buy, Sell or Hold?
• Neutral Sentiment: Valneva investor conference schedule highlights a partner‑related upcoming topline readout (VLA15 Lyme vaccine) that Pfizer expects — a potential future catalyst but not an immediate Pfizer data release. Valneva conference notice
• Neutral Sentiment: Treasury of company commentary: Pfizer’s presentation transcript at the TD Cowen conference gives management color on strategy and pipeline execution but no single market‑moving surprise. TD Cowen presentation transcript
• Negative Sentiment: Pfizer withdrew its EMA filing for Zumrad (an immediate negative for near‑term launch expectations and investor sentiment on that program). This is likely a direct driver of the intraday decline. Pfizer withdraws Zumrad EMA filing
• Negative Sentiment: CEO Albert Bourla publicly flagged issues with FDA vaccine leadership — regulatory tensions can raise uncertainty around approvals and timing for vaccine programs. Reuters: CEO flags FDA leadership issues
• Negative Sentiment: Analysts continue to point to flat guidance, declining COVID sales and upcoming patent cliffs as structural headwinds that temper the stock’s rebound narrative. Zacks: Buy/Sell/Hold analysis

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on PFE shares. HSBC reaffirmed a “buy” rating and issued a $29.00 target price on shares of Pfizer in a research report on Wednesday, December 10th. TD Cowen reissued a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Finally, Barclays assumed coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $28.05.

Pfizer Stock Down 1.3%

The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The stock has a market capitalization of $155.12 billion, a price-to-earnings ratio of 20.06 and a beta of 0.47. The firm’s fifty day moving average is $26.13 and its 200-day moving average is $25.41.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.63 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.3%. Pfizer’s dividend payout ratio is presently 126.47%.

Institutional Investors Weigh In On Pfizer

A number of institutional investors have recently made changes to their positions in PFE. Triad Wealth Partners LLC boosted its holdings in Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 386 shares during the period. ETF Store Inc. lifted its position in shares of Pfizer by 3.8% in the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 396 shares during the last quarter. Mattern Wealth Management LLC boosted its holdings in shares of Pfizer by 4.6% in the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 400 shares during the period. Pines Wealth Management LLC grew its position in shares of Pfizer by 4.4% during the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 400 shares during the last quarter. Finally, Peak Asset Management LLC grew its position in shares of Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after buying an additional 402 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.